These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9351465)

  • 61. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 62. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA; Flaa A; Strand A; Kjeldsen SE
    J Hypertens; 2007 Jan; 25(1):15-23. PubMed ID: 17143167
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
    Peczkowska M; Kabat M; Janaszek-Sitkowska H
    Pol Arch Med Wewn; 1997 Apr; 97(4):379-90. PubMed ID: 9411416
    [No Abstract]   [Full Text] [Related]  

  • 65. [Angiotensin II receptor antagonists. Clinically significant differences].
    Ibsen H; Rasmussen S
    Ugeskr Laeger; 1999 Sep; 161(38):5332-6. PubMed ID: 10536525
    [No Abstract]   [Full Text] [Related]  

  • 66. Cardioprotective effect of angiotensin II receptor antagonists.
    White M
    Can J Cardiol; 1999 Nov; 15 Suppl F():10F-4F. PubMed ID: 10579747
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [New therapeutic principle in the management of cardiac insufficiency: A II antagonists. Results of the ELITE study (Evaluation of Losartan In The Elderly)].
    Dtsch Med Wochenschr; 1997 Sep; 122(39 Suppl):1-4. PubMed ID: 9351465
    [No Abstract]   [Full Text] [Related]  

  • 68. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L; Nagy L
    Orv Hetil; 1997 Oct; 138(41):2583-90. PubMed ID: 9411327
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
    McMurray JJ
    J Renin Angiotensin Aldosterone Syst; 2001 Jun; 2(2):89-92. PubMed ID: 11881104
    [No Abstract]   [Full Text] [Related]  

  • 70. [Losartan--a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure].
    Berezin AE; Fushteĭ IM
    Klin Med (Mosk); 1998; 76(7):12-5. PubMed ID: 9742770
    [No Abstract]   [Full Text] [Related]  

  • 71. [The outlook for the use of the nonpeptide angiotensin II-receptor antagonist losartan in treating heart failure].
    Dunaev VV; Berezin AE
    Eksp Klin Farmakol; 1999; 62(4):77-80. PubMed ID: 10513345
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.